Masimo Proceeds With Danaher Merger Amid Shareholder Lawsuits

Masimo ( (MASI) ) has issued an announcement.

Masimo said it remains on track to be acquired by Danaher under a February 16, 2026 merger agreement, despite a series of shareholder lawsuits and demand letters challenging the adequacy of disclosures in its proxy materials. The company has scheduled a virtual special meeting for May 1, 2026 for shareholders to vote on the deal and continues to recommend approval, while emphasizing that supplemental disclosures will not alter the $180-per-share merger consideration or meeting timing.

Three complaints filed in New York and California in April 2026 seek to block or delay the merger and request damages and fees, alleging Masimo’s definitive proxy statement is incomplete, particularly around the sale process and financial analyses used to support the transaction. Masimo denies the claims but has voluntarily expanded its disclosures, detailing prior sale efforts, bidder outreach, valuation work by Centerview Partners, and board deliberations, in an effort to reduce litigation risk and avoid delays to closing, while warning that additional lawsuits may still be brought.

The newly disclosed background shows Masimo previously ran a broader sale process in 2023–24 that produced no definitive bids amid concerns over ongoing litigation and its consumer assets, and that, in the latest process, competing interest from “Party F” at $186 per share came with a longer timeline and greater execution uncertainty. The board ultimately treated Danaher’s $180-per-share, cash-only proposal as its best executable option, citing Danaher’s insistence that $180 was its “best and final” offer, its expectation of a faster regulatory path, and valuation ranges from precedent and discounted cash flow analyses that framed the offer as financially reasonable for shareholders.

The most recent analyst rating on (MASI) stock is a Hold with a $180.00 price target. To see the full list of analyst forecasts on Masimo stock, see the MASI Stock Forecast page.

Spark’s Take on MASI Stock

According to Spark, TipRanks’ AI Analyst, MASI is a Neutral.

The score is driven by strong cash flow resilience and supportive corporate developments (the $180/share all-cash acquisition agreement and strong preliminary 2025 results). Technicals also show a solid uptrend with positive momentum. Offsetting these positives are weaker profitability/revenue trends in the financial statements and an unattractive/less-informative negative P/E, which keep the overall score in the mid-range.

To see Spark’s full report on MASI stock, click here.

More about Masimo

Masimo Corporation is a medical technology company focused on patient monitoring and related health-care solutions, with operations that have expanded into both core healthcare and non-healthcare consumer businesses. The company has also been involved in significant industry litigation, including disputes with Apple Inc., and has attracted activist investor attention, notably from Politan, which previously gained board representation.

Average Trading Volume: 1,638,962

Technical Sentiment Signal: Strong Buy

Current Market Cap: $9.34B

See more data about MASI stock on TipRanks’ Stock Analysis page.